Stryker reports third quarter 2026 operating results

Stryker’s Q3 2026 sales rose 7.7% to $6.52 billion, while adjusted diluted EPS increased 10.3% to $3.52; reported diluted EPS fell 11.7% to $1.96, including a $293 million goodwill impairment. CEO Kevin Lobo said performance was good in absolute terms but fell short of expectations. The company forecast full-year organic sales growth of 6.5%–7.0% and adjusted diluted EPS of $14.80–$14.90, repurchased $1.0 billion of shares in Q3, and approved a $3.0 billion increase to its repurchase authorization.

Analysis

The key issue is quality of earnings, not the reported EPS decline alone: a large goodwill impairment and other exclusions widen the gap between GAAP and adjusted performance. Adjusted margin expansion is encouraging, but recurring reliance on “special” adjustments makes it important to track whether underlying selling costs and integration spending actually moderate. The goodwill charge also raises a separate question about the returns on acquired assets; it is not proof of broader demand weakness, but warrants scrutiny of the affected business and future impairment risk.

Growth is uneven beneath the consolidated result. Endoscopy and Ortho Tech strength contrasts with near-flat hips and knees, suggesting procedure-enabling technology is outperforming core implant categories. That mix supports Stryker’s near-term resilience but leaves orthopaedics exposed if hospital purchasing or procedure volumes soften. Competitors such as Zimmer Biomet are relevant read-throughs, but the article alone does not establish a relative valuation or performance trade.

Near term, the conference call is the catalyst: management itself says results missed expectations, while the release offers no consensus benchmark or prior guidance for measuring the reset. Over 1–3 months, watch Q4 order/procedure trends, organic growth versus the new outlook, and whether adjusted SG&A leverage persists. Over 6–18 months, buybacks may support per-share growth, but cash returns compete with investment and balance-sheet flexibility; nine-month operating cash flow was also used for dividends, repurchases and capital spending. Contrarian view: the GAAP headline may overstate deterioration, but investors may underweight the credibility cost of recurring exclusions and the quality of growth. Thesis weakens if management signals Q4 deceleration or adjusted margins reverse; it improves if volume-led growth and margin leverage hold without expanding adjustments.

Key Decisions for Investors

• Do not chase SYK before the scheduled call. Reassess after management clarifies what caused the shortfall versus expectations, Q4 demand by segment, and the operational source of the goodwill impairment.
• Conditional trade: if the call confirms stable procedure volumes and sustained adjusted margin leverage, build a measured long SYK against a broad medtech basket after the initial reaction settles; keep exposure modest given the guidance uncertainty. Exit or avoid if Q4 commentary implies organic growth below the updated range or adjusted margin leverage stalls.
• Track GAAP-to-adjusted operating income differences, goodwill and other impairment disclosures, and adjusted SG&A as a share of sales in the next report. Persistent exclusions or renewed expense growth would undercut the quality-of-earnings case.
• Treat the expanded repurchase authorization as optional support, not a committed bid: monitor actual repurchase pace alongside cash generation, debt and capital spending before assigning a meaningful per-share valuation benefit.